Global real-world evidence (RWE) pilot study in antimicrobial resistance (AMR)

The Challenge

The sponsor had a long track record in global AMR surveillance, traditionally reliant on central labs to process and report microbiological data.

But this time, they wanted something more flexible. A faster, decentralised approach that could collect anonymised real-world data — both microbiological and clinical outcomes — directly from hospital sites.

Micron was tasked with enabling this shift: Build a solution that would accept structured data from local LIMS (Laboratory Information Management Systems) where possible, and manually where necessary — all while maintaining data integrity.

Micron's Contribution

Our Approach & Impact

We activated 21 study sites across five countries:

🇮🇳 India, 🇲🇽 Mexico, 🇸🇦 Saudi Arabia, 🇪🇸 Spain, and 🇬🇧 the UK.

Depending on technical capability, each site submitted anonymised data:

• Electronically via their LIMS
• Or manually, supported by Micron’s onboarding and data teams

In total:

• 8,060 hospitalised patient records were submitted
• 7,444 (92%) were complete enough to include in the final analysis
• All data was coded and processed by Micron’s internal data management team

To empower real-time use of the results, we built a secure, web-based portal where both study sites and the sponsor could view and analyse the AMR dataset via a custom database interface.